Cargando…

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis

BACKGROUND: As one of the therapeutic drugs for idiopathic membranous nephropathy (IMN), tacrolimus (TAC) has not been fully vindicated for its efficacy and tolerability. A meta-analysis was performed to detect the efficacy and safety of TAC plus glucocorticoid vs cyclophosphamide (CTX) plus glucoco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wenshan, Li, Hong-Yan, Lin, Shujun, Zhou, Tianbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6613398/ https://www.ncbi.nlm.nih.gov/pubmed/31308629 http://dx.doi.org/10.2147/DDDT.S209211

Ejemplares similares

Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population
por: Lin, Shujun, et al.
Publicado: (2019)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis
por: Zhou, Tianbiao, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
por: Cui, W., et al.
Publicado: (2017)

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials
por: Huang, Haiting, et al.
Publicado: (2021)

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
por: Wang, Qi, et al.
Publicado: (2021)

Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
por: Zhong, Hongzhen, et al.
Publicado: (2020)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Efficacy of mesenchymal stem cells in animal models of lupus nephritis: a meta-analysis
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
por: Chen, Shasha, et al.
Publicado: (2020)

Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2021)

The Efficacy of Mesenchymal Stem Cells in Therapy of Acute Kidney Injury Induced by Ischemia-Reperfusion in Animal Models
por: Zhou, Tianbiao, et al.
Publicado: (2020)

Nephroprotective Effect of Mesenchymal Stem Cell-Based Therapy of Kidney Disease Induced by Toxicants
por: Lin, Shujun, et al.
Publicado: (2020)

Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: Lu, Huijuan, et al.
Publicado: (2022)

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
por: Qin, Hua-Zhang, et al.
Publicado: (2017)

Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy
por: Lv, Wei, et al.
Publicado: (2021)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
por: Ramachandran, Raja, et al.
Publicado: (2017)

Comparison of cyclophosphamide and calcineurin inhibitors for idiopathic membranous nephropathy: A protocol for systematic review and meta-analysis
por: Li, Kang, et al.
Publicado: (2022)

Association of hypoxia-inducible factor-1α (HIF1α) 1790G/A gene polymorphism with renal cell carcinoma and prostate cancer susceptibility: a meta-analysis
por: Li, Hong-Yan, et al.
Publicado: (2019)

Phospholipase‐A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy
por: Xiao, Chunying, et al.
Publicado: (2020)

Retracted: Efficacy and Safety of Rituximab in the Treatment of Idiopathic Membranous Nephropathy: A Meta-Analysis
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Relationship between TGF-β1 + 869 T/C and + 915 G/C gene polymorphism and risk of acute rejection in renal transplantation recipients
por: Li, Hong-Yan, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients
por: Liang, Shuang, et al.
Publicado: (2023)

Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2021)

Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy
por: Mathrani, Vinod, et al.
Publicado: (2017)

Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study
por: Prasad, N., et al.
Publicado: (2018)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults
por: Xiang, Xin, et al.
Publicado: (2021)

Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis
por: Pyo, Jung Yoon, et al.
Publicado: (2021)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis
por: Liu, Jiarong, et al.
Publicado: (2022)

Efficacy and safety of Tripterygium wilfordii multiglucoside for idiopathic membranous nephropathy: a systematic review with bayesian meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2023)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_euc3t7n0idve2uj7op75v1vv0p